Investors & Media

Webcast ImageWebcast
Q2 2015 Isis Pharmaceuticals Earnings Webcast (Live)
08/04/15 at 11:30 a.m. ET
Q2 2015 Isis Pharmaceuticals Earnings Webcast
Tuesday, August 4, 2015 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
Recent Press ReleasesMore >>
DateTitle 
07/29/15Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Publication highlights the therapeutic potential of volanesorsen to address unmet needs in patients with high apoC-III and triglyceride levels CARLSBAD, Calif. and CAMBRIDGE, Mass., July 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating vol... 
Printer Friendly Version
07/28/15Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
- Webcast scheduled on Tuesday, August 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif., July 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A webcast replay will be ... 
Printer Friendly Version
07/27/15Isis Pharmaceuticals Reports Data From ISIS-TTR Rx in Patients With Transthyretin Amyloid-Related Cardiomyopathy
Up to 88 percent reduction in transthyretin protein in patients with TTR-related cardiomyopathy observed CARLSBAD, Calif., July 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by Dr. Merrill Benson at the 20th World Congress on Heart Disease (WCHD) in Vancouver, Canada. "I am encouraged by the sa... 
Printer Friendly Version
07/22/15Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Publication highlights importance of Lp(a) as a risk factor for cardiovascular disease and the therapeutic potential of antisense drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., July 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers with elevated lipoprotein(a) or Lp(a). An accompanying editorial was also publ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
08/04/15 11:30 a.m. ET
Q2 2015 Isis Pharmaceuticals Earnings Webcast

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.